31st week of 2019 patent applcation highlights part 10 |
Patent application number | Title | Published |
20190231745 | INHIBITORS OF T CELL RECEPTOR AND USES THEREOF - The present invention relates to selective inhibitors of TCR, and methods of using the same. | 2019-08-01 |
20190231747 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS - The present invention relates to identification of inhibitors or antagonists of aminoarabinase glycosyltransferase (ArnT) and their use in compositions, methods of treatment or prevention of drug resistant gram negative infections, or inhibiting the growth of gram negative bacterial infections resistant to polymyxin-class antibiotics. In certain aspects, the inhibitors or antagonists can be administered in combination with one or more antibacterial agents. | 2019-08-01 |
20190231748 | COMPOSITION FOR VAGINA AND ANTIMICROBIAL AGENT COMBINATION FOR USE IN PREPARING COMPOSITION FOR VAGINA - The present disclosure relates to an antimicrobial agent combination for use in preparing a composition for vagina. The combination of antimicrobial agents is strong in inhibiting against | 2019-08-01 |
20190231749 | LIQUID PHARMACEUTICAL COMPOSITION OF CLONIDINE - The present invention relates to liquid pharmaceutical composition suitable for oral administration comprising clonidine or pharmaceutically acceptable salts thereof with at least one buffer and at least one preservative. The present invention also relates to process for preparing the said liquid pharmaceutical composition. | 2019-08-01 |
20190231750 | Methods and Compositions for Treating Cutaneous Fungal Infections - The present invention relates to methods and compositions for the treatment of dermatophytic conditions such as tinea pedis. Such conditions can progress through multiple stages, such as fungal and bacterial stages, making effective treatment results difficult to achieve. The invention relates to a combined therapy effective for treatment of the condition that utilizes daily administration of a balanced combination of antifungals, antiperspirants and drying agents to achieve a beneficial therapeutic effect, irrespective of the stage of the disease upon commencement of the treatment. | 2019-08-01 |
20190231751 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS - The present disclosure provides a method of treating diseases, conditions or disorders associated with fibrosis in a mammal using inhibitors of the Jun N-terminal kinase (JNK) pathway. The present disclosure in particular provides methods of treating diseases, conditions or disorders associated with fibrosis using a specific class of small molecule JNK inhibitors. | 2019-08-01 |
20190231752 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS - This invention pertains generally to antibacterial compounds of Formula I, | 2019-08-01 |
20190231753 | METHOD OF TREATMENT OF SHWACHMAN-DIAMOND SYNDROME - The invention relates to compounds for the treatment of ribosomopathies. In particular, it refers to compounds for the treatment of Shwachman-Diamond Syndrome (SDS) and other ribosomopathies, such as Diamond-Blackfan Anemia (DBA), X-linked dyskeratosiscongenita (DKC) and Treacher Collins syndrome (TCS). | 2019-08-01 |
20190231754 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE - The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay. | 2019-08-01 |
20190231755 | METHOD FOR PRODUCING SOLID DISPERSION COMPRISING RAPAMYCIN DERIVATIVE - It is an object of the present invention to provide a solid dispersion, which suppresses a reduction in the content of an active ingredient caused by oxidation or decomposition of rapamycin or a derivative thereof, can ensure long-term stability, and has high safety. According to the present invention, there is provided a method for producing a solid dispersion comprising, as an active ingredient, rapamycin or a derivative thereof, wherein the method comprises: a first step of mixing a first solvent that is a protic polar solvent, a second solvent that is an aprotic solvent, a water-soluble polymeric carrier, and rapamycin or a derivative thereof, wherein the ratio of the first solvent is higher than 50% by volume of the total volume of the first solvent and the second solvent; and a second step of removing the solvents. | 2019-08-01 |
20190231756 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF - Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers. | 2019-08-01 |
20190231757 | COMBINATION OF SPLEEN TYROSINE KINASE INHIBITORS AND OTHER THERAPEUTIC AGENTS - This disclosure provides combination therapies for treating cancers. In particular, this disclosure provides methods for treating non-Hodgkin lymphoma comprising administering a combination of a SYK inhibitor and a second therapeutic agent. | 2019-08-01 |
20190231759 | THERAPEUTIC TARGETING OF PROTEOLYTIC CLEAVAGE OF THE MIXED LINEAGE LEUKEMIA GENE PRODUCT (MLL1) BY TASPASE1 USING KINASE INHIBITORS - Disclosed are methods and pharmaceutical compositions for treating a cancer in a subject in need thereof, the cancer characterized by proteolytic cleavage by taspase1 of the mixed-lineage leukemia 1 gene product (MLL1), the method comprising administering to the subject a therapeutic agent that inhibits cleavage by taspase1 of MLL1. Suitable therapeutic agents may include agents that inhibit the kinase activity of casein kinase II (CKII). Cancer treated by the disclosed methods and pharmaceutical compositions may include leukemia such as Acute Lymphoblastic Leukemia (ALL) and/or Acute Myeloid Leukemia (AML) and in particular, leukemia characterized by rearrangements in MLL1. | 2019-08-01 |
20190231760 | USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS - The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof | 2019-08-01 |
20190231761 | COMPOSITIONS AND METHODS FOR TARGETING FRUCTOSE ENZYMES AND TRANSPORTERS FOR THE TREATMENT OF CANCER - The disclosure relates to compositions and methods of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a therapeutic agent capable of down-regulating and/or inhibiting a fructose enzyme or fructose transporter in a cell of the subject such that the cancer growth is suppressed. | 2019-08-01 |
20190231762 | CONTROLLED DELIVERY SYSTEM - The present invention relates to novel anesthetic compositions containing a non-polymeric carrier material and an anesthetic, where the compositions are suitable for providing a sustained local anesthesia without an initial burst and having a duration for about 24 hours or longer. Certain compositions are also provided that include a first anesthetic and a second anesthetic. In such compositions, the second anesthetic is a solvent for the first anesthetic and provides an initial anesthetic effect upon administration to a subject. The non-polymeric carrier may optionally be a high viscosity liquid carrier material such as a suitable sugar ester. The compositions can further include one or more additional ingredients including active and inactive materials. Methods of using the compositions of the invention to produce a sustained anesthetic effect at a site in a subject are also provided. | 2019-08-01 |
20190231763 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2019-08-01 |
20190231764 | MEDICINAL COMPOSITION FOR INHALATION - The present invention provides a particle comprising pirfenidone and a lipid, particularly magnesium stearate, and having a mean particle diameter of 5 μm or less, and a powder formulation comprising the particle and a carrier. | 2019-08-01 |
20190231765 | METHODS FOR TREATING OCULAR DISEASE USING INHIBITORS OF CSF-1R - The present invention provides in one aspect methods for treating ocular diseases by administering pharmaceutical compositions comprising an inhibitor of colony stimulating factor-1 (CSF-1) receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one inhibitor of CSF-1R. The inhibitor can also be a selective inhibitor of CSF-1R in certain embodiments. | 2019-08-01 |
20190231766 | ADMINISTRATION OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYL-AMINOIMINOMETHYL)PHENYL-AMINO]METHYL}-1-METHY- L-1H-BENZIMIDAZOL-5-CARBONYL)PYRIDIN-2-YLAMINO]PROPIONATE - The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof. | 2019-08-01 |
20190231767 | COMBINATION OF PIMAVANSERIN AND CYTOCHROME P450 MODULATORS - A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor. | 2019-08-01 |
20190231768 | PRIDOPIDINE FOR TREATING DRUG INDUCED DYSKINESIAS - The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions. | 2019-08-01 |
20190231770 | COMBINATION COMPOSITIONS COMPRISING FXR AGONISTS FOR TREATING OR PREVENTING A FIBROTIC, CIRRHOTIC DISEASE OR DISORDER - The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist and another therapeutic agent, in particular for treating or preventing liver diseases or disorders. | 2019-08-01 |
20190231772 | TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT - The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists. | 2019-08-01 |
20190231773 | CGRP RECEPTOR ANTAGONISTS - The disclosures herein relate to novel compounds of formula | 2019-08-01 |
20190231774 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 2019-08-01 |
20190231775 | Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase - In some embodiments, the present invention relates to novel small molecule inhibitors that block the CXCR4-SDF-1 signaling pathway by directly inhibiting members of the Tec family of kinases, namely Bruton's tyrosine kinase (BTK), and their use in treating diseases in which pathogenesis is mediated by the CXCR4/SDF-1 signaling pathway. | 2019-08-01 |
20190231776 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS - The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1. | 2019-08-01 |
20190231777 | Trk-INHIBITING COMPOUND - The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. | 2019-08-01 |
20190231778 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor. | 2019-08-01 |
20190231779 | METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF ABNORMAL BONE FORMATION IN A SOFT TISSUE - Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification. | 2019-08-01 |
20190231780 | ORGANIC COMPOUNDS - The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms. | 2019-08-01 |
20190231781 | TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | 2019-08-01 |
20190231782 | TOPICAL FORMULATIONS COMPRISING TOFACITINIB - A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation. | 2019-08-01 |
20190231783 | PHARMACEUTICAL FORMULATIONS - The disclosure provides, inter alia, compositions, oral formulations, amorphous solid dispersions, extrudates, crystalline nanoparticles, and microprecipitated bulk powders containing adenosine A2A receptor antagonists, and methods of using the compositions, oral formulations, amorphous solid dispersions, extrudates, crystalline nanoparticles, and microprecipitated bulk powder to treat cancer. | 2019-08-01 |
20190231784 | MODIFIED RELEASE FORMULATIONS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]- PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-EN- ENITRILE - Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations. | 2019-08-01 |
20190231785 | PHOSPHODIESTERASE INHIBITOR TREATMENT - Methods and compositions are disclosed for the treatment of taste and smell disorders. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal administration. | 2019-08-01 |
20190231786 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES - Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H | 2019-08-01 |
20190231787 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES - Methods and compounds for treating alcohol use disorder and associated diseases. Included is the administering to a subject in need there of an effective amount of a compound having a modulating effect on p75NTR. | 2019-08-01 |
20190231788 | COMPOSITIONS COMPRISING TIMOLOL AND AN ANTI-INFLAMMATORY AGENT - The present invention relates to combinations comprising timolol and a compound useful for the treatment of rosacea selected from ivermectin, metronidazole and praziquantel and to the use of these combinations in the topical treatment of rosacea. | 2019-08-01 |
20190231789 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF - This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes. | 2019-08-01 |
20190231790 | USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS - The present invention provides compounds of the formula (I) | 2019-08-01 |
20190231791 | Combination Therapy - The present invention provides a method of treating a cognitive or neu-rodegerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula (I):or a pharmaceutically acceptable salt thereof in combination with an effective amount of an anti-N3pGlu Abeta antibody selected from the group consisting of hE8L, B12L, R17L, Antibody I, and Antibody II. | 2019-08-01 |
20190231792 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain. | 2019-08-01 |
20190231793 | USE OF HARRINGTONINES IN THE TREATMENT OF BREAST CANCER, IN PARTICULAR TRIPLE-NEGATIVE BREAST CANCER - The present invention relates to harringtonine, homoharringtonine and/or derivatives thereof, in particular compounds of formula 1a to 1g as defined in table 1, more particularly in the form of salt, preferably crystalline salt, for use in the treatment or prevention of breast cancer, in particular triple-negative breast cancer (TNBC). | 2019-08-01 |
20190231794 | TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA - A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided. | 2019-08-01 |
20190231795 | METHODS FOR TREATING CANCER AND PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS - Featured are methods of treating a patient with cancer by administering, e.g., a secretory phospholipase A | 2019-08-01 |
20190231796 | COMPOSITIONS COMPRISING HYDROXYTYROSOL AND BOSWELLIC ACID - Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-β-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-β-boswellic acid may be sourced from a | 2019-08-01 |
20190231797 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS - Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same. | 2019-08-01 |
20190231798 | COMPOSITIONS AND METHODS FOR THE REPAIR OF MYELIN - Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder. | 2019-08-01 |
20190231799 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES - Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition. | 2019-08-01 |
20190231800 | CO-CRYSTALS OF TRAMADOL AND COXIBS - The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain. | 2019-08-01 |
20190231801 | METHODS OF TREATING OVARIAN CANCER - Disclosed herein are methods of treating ovarian cancer comprising administering to a subject in need thereof an effective amount of methacycline, or a pharmaceutically acceptable salt thereof. The methacycline can be administered as part of treatment regimen, which also can include other chemo- or immune-therapies, radiation therapy, and/or surgical treatments. | 2019-08-01 |
20190231802 | CHEMOTHERAPEUTIC-RELEASING IMPLANTABLE STICK, METHODS OF MANUFACTURE AND PRECURSOR MATERIALS - A chemotherapeutic-releasing implantable stick is described herein. The chemotherapeutic-releasing implantable stick includes an implantable stick having a length and thickness to fit within a needle track from a needle biopsy, the implantable stick providing a biocompatible and biodegradable substrate for the release of a chemotherapeutic agent when implanted. The chemotherapeutic-releasing implantable stick further includes a chemotherapeutic agent absorbed into the implantable stick. | 2019-08-01 |
20190231803 | ISOTOPOLOGUES OF 5-AZACYTIDINE - The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein. | 2019-08-01 |
20190231804 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION - Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, | 2019-08-01 |
20190231805 | SHP2 INHIBITORS AND METHODS OF USE THEREOF - Provided are methods for the treatment of insulin resistance and insulin receptor diseases with SHP2 inhibitors, such as allosteric inhibitors of SHP2 and RNAi or siRNA that target SHP2 expression. Compositions and methods for delivery of SHP2 inhibitors, such as liver-targeting liposomes or nanoparticles, are also provided. | 2019-08-01 |
20190231806 | Metformin Compositions and Methods for Treatment of Diabetes - The invention provides compositions and methods to treat diabetes with improved formulations in which metformin is combined with at least three antioxidants that contain a stabilizing heteroatom adjacent to a saturated carbon and which help maintain a balance between antioxidant and pro-oxidant properties. The antioxidants include at least the combination of taurine, citrulline and methylcobalamin, and optionally include melatonin. The composition provides management of blood glucose levels comparable to metformin in the same dose without antioxidants, without the phenomenon of undermining metformin performance that is commonly observed in the presence of co-administered antioxidants. | 2019-08-01 |
20190231807 | Folic Compositions and Methods for Treatment of Diabetic Neuropathies - The invention provides compositions and methods to treat diabetic neuropathies. In particular the invention has discovered that, in combination with a folic compound, particular combinations of two types of additional antioxidants have complementary effects for use against diabetic neuropathies. These include antioxidants that comprise stabilizing heteroatoms and antioxidants with an extended conjugated segment, where at least one of the antioxidants that comprises a stabilizing heteroatom also has pro-oxidant effects. | 2019-08-01 |
20190231808 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EXPANDED REPEAT-ASSOCIATED DISORDERS - Translation modulating agents that modulate expression of one or more translation start sites for expanded repeat (e.g., DPR) protein synthesis are provided. Compositions and methods for treating translation start sites for expanded repeat (e.g., DPR) protein synthesis-associated disorders are also provided. | 2019-08-01 |
20190231809 | MODULATION OF MICRORNAS AGAINST MYOTONIC DYSTROPHY TYPE 1 AND ANTAGONISTS OF MICRORNAS THEREFOR - Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs therefor. The invention provides the use of inhibitors of microRNAs repressors of MBNL1 and/or MBNL2 genes for the manufacture of a medicinal product for the treatment of myotonic dystrophy 1. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2, thereby alleviating symptoms of the disease, especially when inhibiting repressors that are expressed in the main affected organs: skeletal muscle, heart or organs of the central nervous system. The inhibition of the microRNAs miR-23b-3p and miR-218-5p is preferred. It also provides oligoribonucleotide or oligoribonucleotide analogue antagonists suitable therefor, preferably antagomiRs directed against the microRNAs mentioned with chemical modifications that enhance their interaction with the target, their stability in vivo and their ability to penetrate into the cells and distribute throughout tissues and organs. | 2019-08-01 |
20190231810 | LOW POLYDISPERSITY, LOW MOLECULAR WEIGHT BIOTECHNOLOGICAL CHONDROITIN SULFATE WITH ANTI-INFLAMMATORY AND ANTIARTHRITIS ACTIVITY AND USE THEREOF IN THE PREVENTION OF OSTEOARTHRITIS - Disclosed is a low molecular weight (1000-5000 daltons) chondroitin sulfate (CS) produced by chemical sulfation of a non-sulfated chondroitin backbone (K4 capsular polysaccharide) obtained with biotechnology techniques. The CS described is substantially monosulfated, mainly at the 6-position, with very little sulfation at the 4-position, and with a mono/disulfated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin sulfate (CS) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes. | 2019-08-01 |
20190231811 | LUBRICATING BLOCK COPOLYMERS AND THEIR USE AS BIOMIMETIC BOUNDARY LUBRICANTS - The invention relates to methods of lubricating biological tissue, such as joints, bone, ocular tissue, nasal tissue, tendons, tendon capsule, and vaginal tissue, by contacting the biological tissue with an effective amount of a block copolymer lubricating composition which functions at least or better than lubricin. In particular embodiments, the method is used to treat osteoarthritis. In specific embodiments, the block copolymer has an ammonium-containing polymer block and a non-ionic hydrophilic polymer block, or the copolymer has a carboxylic acid-containing polymer block and a non-acid non-ionic hydrophilic polymer block. | 2019-08-01 |
20190231812 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION - Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. | 2019-08-01 |
20190231813 | Compositions of Oral Alkaline Salts and Metabolic Acid Inducers and Uses Thereof - Compositions of alkaline salts and metabolic acid inducers and methods of use thereof are provided. The disclosed compositions may be used for stimulating vagal nerve efferent pathways, treating or preventing an inflammatory response or an autoimmune disorder, inhibiting or reducing one or more inflammatory M1 macrophages and/or one or more inflammatory neutrophils in the blood, promoting polarization of macrophages from a pro-inflammatory M1 state to an anti-inflammatory M2 state, and treating or preventing cardiovascular disease or metabolic disorders. | 2019-08-01 |
20190231814 | Methods of Administering Inhaled Nitric Oxide Gas - The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide. | 2019-08-01 |
20190231815 | COMPOSITIONS COMPRISING COPPER CHELATORS AND METHODS OF USE THEREOF FOR TREATING VASCULOPATHIES - The present invention relates to copper chelator compounds and their use for treating vasculopathies, for example, pulmonary hypertension (e.g., pulmonary arterial hypertension or portopulmonary hypertension). The methods include administering a composition comprising an effective amount of a copper chelator compound to a patient in need thereof. Administration can be via oral, intraperitoneal, transdermal, intravenous and inhalation routes. In another aspect of the invention, compositions are provided comprising a copper chelator compound complexed to or encapsulated by a lipid component, for example, a copper chelator encapsulated by a liposome and methods of treatment employing the same. | 2019-08-01 |
20190231816 | COMBINATION THERAPY EFFECTIVE IN THE TREATMENT OF AGEING AND AGE-RELATED DISORDERS - The present invention provides a pharmaceutical preparation and in particular a combination of a pharmaceutical preparation and hyaluronic acid for use as a medicament, wherein the pharmaceutical preparation is injected into an intact skin and is preparable by a production method comprising the steps of providing a liquid collected from an organism, which liquid comprises cellular constituents of blood, providing a vessel or containment means, said vessel or containment means having an internal surface, and contacting said liquid with said vessel or containment means, wherein
| 2019-08-01 |
20190231817 | METHODS OF GENERATING T-CELLS FROM STEM CELLS AND IMMUNOTHERAPEUTIC METHODS USING THE T-CELLS - Methods and composition for production of T cells are provided. Also provided are therapeutic methods using engineered T cells. For example, in certain aspects methods include preparing three dimensional cell culture compositions comprising stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T cells. | 2019-08-01 |
20190231818 | IMMUNE EFFECTOR CELLS PRE-INFECTED WITH ONCOLYTIC VIRUS - Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics. | 2019-08-01 |
20190231819 | SLIT2D2-CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF - A chimeric antigen receptor (CAR) and a gene encoding the CAR. The CAR comprises an extracellular domain capable of binding to an antigen, a transmembrane domain, and intracellular immune co-stimulatory molecule, wherein the extracellular domain comprises a D2 domain of a Slit2 protein. A chimeric antibody-expressing cell, which introduces a gene encoding the CAR into a cell so as to express the CAR on the surface of the cell. The CAR or CAR-expressing cell can be used as a cell drug for the treatment of tumor diseases. By using the CAR for engineering cells, especially T cells, the engineered T cells can specifically recognize and kill tumors, and have higher tumoricidal activity. | 2019-08-01 |
20190231820 | METHODS OF USING TUMOR INFILTRATING LYMPHOCYTES IN DOUBLE-REFRACTORY MELANOMA - Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed. Also disclosed is the use of IP-10 as a biomarker for predicting treatment efficacy. | 2019-08-01 |
20190231821 | HERV-E REACTIVE T CELL RECEPTORS AND METHODS OF USE - Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an α chain (such as SEQ ID NO: 2) and a β chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR α and/or β chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR α chain and the TCR β chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR α chain and the TCR β chain, and administering a composition comprising the modified T cells to the subject. | 2019-08-01 |
20190231822 | METHODS OF REDUCING CHRONIC GRAFT-VERSUS-HOST DISEASE - Methods of reducing or reversing chronic graft-versus-host-disease (cGVHD) are provided herein. | 2019-08-01 |
20190231823 | REJUVENATED AGED HEMATOPOIETIC STEM CELLS AND METHODS OF USE - The invention relates to rejuvenated hematopoietic stem cells and methods of use. | 2019-08-01 |
20190231824 | CELL LAMINATE, METHOD FOR PRODUCING CELL LAMINATE, METHOD FOR EVALUATING EPIDERMAL PROLIFERATION OR DIFFERENTIATION, METHOD FOR EVALUATING TEST SUBSTANCE, AND BIOLOGICAL IMPLANTATION MATERIAL - Disclosed herein are a cell laminate including an epidermal layer in which specific gene-deficient epidermal keratinocytes are laminated; a method for producing a cell laminate, including a step of culturing specific gene-deficient epidermal keratinocytes by air-liquid interface culture; and applications thereof. | 2019-08-01 |
20190231825 | Process for Producing Egg Yolk With High Content of AF-16 - The present invention relates to a process for producing an egg yolk with a very high content of antisecretory factor (AF) proteins, in particular with a very high content of AF protein fragment consisting essentially of the amino acid sequence as shown in SEQ.ID.NO.1 (AF-16) and/or in SEQ.ID.NO.2 (AF-8), said process comprising for at least 4 weeks feeding a poultry, such as a hen, an AF-16 inducing pelleted feed for poultry comprising at least 0.14% free tryptophan, such as 1-2 g tryptophan/kg feed, and thereafter harvesting egg from said poultry, separating egg yolk from egg white, and alternatively spray-drying, grinding, leaching, extracting, evaporating, membrane filtrating, and/or or freeze-drying said egg yolk. | 2019-08-01 |
20190231826 | BEE-INGESTIBLE COMPOSITIONS, METHODS OF USING SAME FOR PRODUCING HONEY AND HONEY PRODUCED THEREBY - A bee ingestible composition comprising a bee food base and THC and/or CBD is provided. Also provided are methods of producing honey, honey obtainable by these methods and uses of same. | 2019-08-01 |
20190231827 | AMOEBA THERAPEUTIC DRESSINGS, BIOMATERIALS, AND SOLUTIONS - A method of treating or preventing a microbial infection in a subject is described. The method includes contacting a microorganism within the subject with a composition comprising one or more species of amoebae of the genus | 2019-08-01 |
20190231828 | METHODS OF MICROBIAL TREATMENT OF POULTRY - Disclosed are methods of administering one or more | 2019-08-01 |
20190231829 | Compositions and Methods for Treating Immune Disorders Using Immune Modulating Lactococcus Bacteria Strains - Provided herein are methods and compositions related to immune modulating | 2019-08-01 |
20190231830 | COMPOSITION CONTAINING BIFIDOBACTERIUM FOR ALLEVIATING, PREVENTING OR TREATING RHEUMATOID ARTHRITIS - Provided is a composition containing | 2019-08-01 |
20190231831 | NOVEL BORDETELLA BRONCHISEPTICA BACTERIOPHAGE BOR-BRP-1, AND USE THEREOF FOR INHIBITION OF PROLIFERATION OF BORDETELLA BRONCHISEPTICA BACTERIA - The present invention relates to a Podoviridae bacteriophage Bor-BRP-1 (accession no. KCTC 12705BP) isolated from nature, which has an ability to specifically kill | 2019-08-01 |
20190231832 | COMPOSITIONS AND METHODS FOR ENHANCING GROWTH, SPREAD, AND ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF ONCOLYTIC RNA VIRUSES - Provided herein are methods for enhancing infection, growth, spread, or titer of an oncolytic RNA virus in a cancer or tumor cell; enhancing the oncolytic activity, cytokine-induced cell death activity, and/or cytotoxic activity of an oncolytic RNA virus in a cancer or tumor cell; upregulating cytokine response to, and/or enhancing the immunotherapeutic activity of an oncolytic RNA virus in a cancer or tumor cell; and/or treating a tumor or cancer in a subject in need thereof. Such methods employ a vanadium-containing compound, administered to the cancer or tumor cells before, after, or concurrently with infection of the cancer or tumor cells with the oncolytic RNA virus. Related compositions, uses, and kits therefor are also provided. Methods for producing RNA viruses, RNA virus-based cancer vaccines, and RNA virus-based cancer gene therapy vectors are also provided. | 2019-08-01 |
20190231833 | METHOD FOR SELECTIVE EXTRACTION OF CANNABINOIDS FROM A PLANT SOURCE - Provided are methods for selective extraction of cannabinoids, for example cannabidiol (CBD), from a plant source, by using tailored extraction media. | 2019-08-01 |
20190231834 | METHODS FOR MAKING YERBA MATE EXTRACT COMPOSITION - Methods are described herein for making a composition comprising at least one of caffeic acid, monocaffeoylquinic acids, and dicaffeoylquinic acids, and salts thereof. | 2019-08-01 |
20190231835 | PHARMACEUTICAL COMPOSITION CONTAINING SOPHORA JAPONICA L. EXTRACT AS ACTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS - Provided is a pharmaceutical composition containing, as an active ingredient, a | 2019-08-01 |
20190231836 | METHOD AND COMPOSITIONS FOR THE USE OF BOTANICAL EXTRACTS IN THE TREATMENT OF VIRAL INFECTIONS, CANCER, PAIN, ITCH, AND INFLAMMATION - The present disclosure relates generally to the preparation and use of certain botanical extracts and therapeutic compositions for the treatment of viral infections, cancer, pain, itch, and inflammation. The present disclosure generally relates to antiviral compositions, and more specifically to the preparation of botanical extracts and their use in the treatment of viral infections, cancer, pain associated conditions. | 2019-08-01 |
20190231837 | OLIVE DERIVED CELL CULTURE AND METHODS FOR PREPARING AND USING THE SAME - The present application describes a large process for the in vitro production of an olive cell culture. | 2019-08-01 |
20190231838 | BIOACTIVE COMPOSITIONS FROM FRUIT AND METHODS FOR THEIR PRODUCTION - The present invention relates to bioactive fractions (ingredients) derived from fruit juices. The bioactive fractions are either free of or substantially free of patulin and protein. Further, the bioactive fractions have antioxidant, free radical scavenging, moisturizing and buffering properties. The present invention also relates to a method for isolating bioactive fractions that are derived from fruit juices and are free or substantially free of protein and patulin. The present invention also relates to a method for preparing a bioactive fractions derived from fruit juices that are stabilized and are either free of or substantially free of patulin and protein. | 2019-08-01 |
20190231839 | TRADITIONAL CHINESE MEDICINE COMPOSITION COMPRISING DRIED TANGERINE PEELS AND DARK TEA FOR TREATING DIABETES AND PREPARATION METHOD THEREOF - A traditional Chinese medicine composition for treating diabetes and a preparation method thereof, the composition comprises dried tangerine peels and dark tea. The preparation method utilizes Pu'er tea to shuffle placement with the dried tangerine peels to preserve the dried tangerine peels, mixes different kinds of dried tangerine peels of different aging years, adds the mixed dried tangerine peels with pile-fermented black tea, presses the mixed black tea into tea bricks, and secondarily-ferments the tea bricks, then ages the secondary fermented tea bricks for two years. | 2019-08-01 |
20190231840 | PLANT BASED EMOLLIENT - The disclosure relates to a plant based emollient composition. The composition includes coconut oil and an aloe vera plant extract. The composition is useful alone or as a vehicle for small quantities of herbs, vitamins, medications, minerals, vinegars, essential oils (as examples) added during the composition's liquid phase. | 2019-08-01 |
20190231841 | CENCHRUS CILIARIS L. AS AN ANTICANCER AGENT - L. as an anticancer agent was obtained by separately extracting the aerial parts of the plant and the root part of the plants. Extractions were performed first in ethanol, and then a portion successively in water, chloroform, and aqueous butanol. All extracts were tested for cytotoxicity against six cancer cell lines. Generally, the root extracts exhibited greater cytotoxicity than the aerial extracts. The highest anticancer effects for both aerial and root extracts were shown against hepatocellular cancer, colorectal cancer, and lung cancer, compared to the other cell lines tested. The chloroform extracts showed greater anticancer effects, both for aerial and root extracts. | 2019-08-01 |
20190231842 | HIGHLY CONCENTRATED FORMULATIONS OF SOLUBLE Fc RECEPTORS - The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc | 2019-08-01 |
20190231843 | METHODS OF PRODUCING ANAMORELIN HYDROCHLORIDE HAVING CONTROLLED CHLORIDE CONTENT - The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms. | 2019-08-01 |
20190231844 | ORAL APPLICATION OF THIOPEPTCIN - Provided in the present invention are a new use of thiopeptin in the preparation of drugs for treating diseases caused by | 2019-08-01 |
20190231845 | Reagents and methods for treating bacterial infection - Disclosed herein are α-sheet peptides and their use for treating a bacterial infection and/or limiting bacterial biofilm formation. | 2019-08-01 |
20190231846 | LIGHT-SENSITIVE PUMPS FOR SUPPRESSION OF CARDIAC ACTIVITY - The present invention relates to methods for attenuating cardiac activity, thereby treating cardiac disease and disorders associated with irregular or increased cardiac activity. | 2019-08-01 |
20190231847 | TREATMENT OF OCULAR DISEASE - A treatment of ocular disease, and more specifically disorders of the cornea, using the polypeptide FKBP-L and peptide fragments thereof is provided. | 2019-08-01 |
20190231848 | POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISORDERS - This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders. | 2019-08-01 |